The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
Germany
University Hospital Tuebingen, Tübingen, Baden-Wurttemberg University hospital Heidelberg, Heidelberg, BadenWuerttemberg Age range
18 Years and older
Last updated December 2024